Immunisation with a pneumococcal 7-valent conjugate vaccine

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


Pneumococcal disease causes approximately 1 million deaths a year worldwide in children aged younger than 5 years. Increasing antibiotic-resistant strains have made management of pneumococcal disease difficult. A pneumococcal 7-valent conjugate vaccine (PNCRM7) has been shown to prevent invasive disease in young children; it has also demonstrated a modest impact on the prevention of otitis media. This conjugated vaccine provides a consistent immune response in infants and young children and can be administered simultaneously with other childhood vaccines. It is generally well tolerated, with local reactions similar to those observed with other licensed childhood vaccines. The objective of this review is to discuss the clinical efficacy, immunogenicity and safety of PNCRM7.

Original languageEnglish
Pages (from-to)287-291
Number of pages5
JournalInternational Journal of Clinical Practice
Issue number4
StatePublished - 24 Jun 2002
Externally publishedYes

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Immunisation with a pneumococcal 7-valent conjugate vaccine'. Together they form a unique fingerprint.

Cite this